EMCURE Emcure Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall
Emcure Pharmaceuticals reported a robust Q1 FY26, achieving its highest-ever quarterly profit of INR 215 crores, driven by strong growth across both domestic and international segments. The company's strategic focus on new initiatives, partnerships, and product innovation is yielding positive results, with significant margin expansion targeted over the next few years. Despite global funding challenges in ARV and potential US tariffs, Emcure remains insulated due to its low US market exposure.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 2,002 | 1,963 | 2,116 | 2,101 |
| EBITDA | 381 | 355 | 402 | 417 |
| Net profit | 202 | 156 | 197 | 215 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
